LLY

767.59

-2.16%↓

JNJ

149.75

-0.73%↓

NVO

74.15

+0.08%↑

ABBV

184.93

-0.24%↓

UNH

303.61

-1.13%↓

LLY

767.59

-2.16%↓

JNJ

149.75

-0.73%↓

NVO

74.15

+0.08%↑

ABBV

184.93

-0.24%↓

UNH

303.61

-1.13%↓

LLY

767.59

-2.16%↓

JNJ

149.75

-0.73%↓

NVO

74.15

+0.08%↑

ABBV

184.93

-0.24%↓

UNH

303.61

-1.13%↓

LLY

767.59

-2.16%↓

JNJ

149.75

-0.73%↓

NVO

74.15

+0.08%↑

ABBV

184.93

-0.24%↓

UNH

303.61

-1.13%↓

LLY

767.59

-2.16%↓

JNJ

149.75

-0.73%↓

NVO

74.15

+0.08%↑

ABBV

184.93

-0.24%↓

UNH

303.61

-1.13%↓

Search

Alkermes PLC

Open

SectorGezondheidszorg

29.1 -0.61

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.1

Max

29.47

Belangrijke statistieken

By Trading Economics

Inkomsten

-124M

22M

Verkoop

-123M

307M

K/W

Sectorgemiddelde

14.205

50.857

EPS

0.291

Winstmarge

7.329

Werknemers

1,800

EBITDA

-168M

14M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+37.85% upside

Dividenden

By Dow Jones

Volgende Winsten

23 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-906M

4.9B

Vorige openingsprijs

29.71

Vorige sluitingsprijs

29.1

Nieuwssentiment

By Acuity

50%

50%

154 / 381 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Alkermes PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

19 jun 2025, 15:04 UTC

Acquisities, Fusies, Overnames

UniCredit's Banco BPM Bid Gets Conditional EU Nod -- Update

19 jun 2025, 14:33 UTC

Acquisities, Fusies, Overnames

UniCredit's Banco BPM Bid Gets Conditional EU Nod

19 jun 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

19 jun 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

19 jun 2025, 20:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

19 jun 2025, 20:38 UTC

Acquisities, Fusies, Overnames

Home Depot Bid Kicks Off a Battle for $5 Billion Building-Products Company -- WSJ

19 jun 2025, 20:38 UTC

Acquisities, Fusies, Overnames

Home Depot Privately Made Bid for Building-Products Distributor GMS, Sources Say -- WSJ

19 jun 2025, 20:38 UTC

Acquisities, Fusies, Overnames

Competing Offers Could Prompt Bidding War for GMS, Sources Say -- WSJ

19 jun 2025, 20:38 UTC

Acquisities, Fusies, Overnames

Offer From Home Depot Comes as QXO Makes Unsolicited Proposal at $95.20 Per Share -- WSJ

19 jun 2025, 17:02 UTC

Acquisities, Fusies, Overnames

Worthington Buys Elgen Manufacturing for About $93M, Funded With Cash on Hand

19 jun 2025, 17:01 UTC

Acquisities, Fusies, Overnames

Worthington Enterprises Says Elgen Will Become Part of Its Building Products Segment

19 jun 2025, 17:01 UTC

Acquisities, Fusies, Overnames

Worthington Enterprises Acquires Elgen Manufacturing >WOR

19 jun 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

19 jun 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

19 jun 2025, 15:37 UTC

Marktinformatie

European Gas Soars on Middle East Escalation Fears -- Market Talk

19 jun 2025, 15:16 UTC

Marktinformatie

Copper Prices Look Set to Fall Over Third Quarter, Citi Says -- Market Talk

19 jun 2025, 15:16 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

19 jun 2025, 15:10 UTC

Marktinformatie

Dollar Rises as Israel-Iran Conflict Intensifies -- Market Talk

19 jun 2025, 15:10 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

19 jun 2025, 15:02 UTC

Marktinformatie

Oil Climbs 2% as Israel-Iran Tensions Mount, With U.S. Role in Focus -- Market Talk

19 jun 2025, 14:15 UTC

Acquisities, Fusies, Overnames

EU: UniCredit Committed to Divest 209 Physical Branches in Overlap Areas Across Italy

19 jun 2025, 14:15 UTC

Acquisities, Fusies, Overnames

EU: UniCredit Commitments Fully Address Competition Concerns Identified

19 jun 2025, 14:15 UTC

Acquisities, Fusies, Overnames

EU Rejected Request From Italian Competition Authority to Refer Deal for National Review

19 jun 2025, 14:15 UTC

Acquisities, Fusies, Overnames

EU Approves UniCredit's Acquisition of Banco BPM, Subject to Conditions

19 jun 2025, 14:15 UTC

Acquisities, Fusies, Overnames

EU Says There Are No Compelling Reasons to Justify Referral to Italy

19 jun 2025, 13:58 UTC

Marktinformatie

Market Talk Roundup: BOE Holds Rates as Focus Turns to Likely August Cut

19 jun 2025, 13:58 UTC

Marktinformatie

Market Talk Roundup: BOE Holds Rates as Focus -2-

19 jun 2025, 13:38 UTC

Marktinformatie

Canadian Small Firms Appear to Be Coping With Tariffs -- Market Talk

19 jun 2025, 13:33 UTC

Marktinformatie

BOE Likely to Cut Rates If Firms' Pricing Power Weakens -- Market Talk

19 jun 2025, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Alkermes PLC Prognose

Koersdoel

By TipRanks

37.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 40.43 USD  37.85%

Hoogste 52 USD

Laagste 30 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alkermes PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

9

Buy

5

Hold

0

Sell

Technische score

By Trading Central

27.95 / 30.91Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

154 / 381 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.